Lin I.-H.BO-I KUOLiu F.-Y.2021-11-082021-11-0820211010-660Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85105235757&doi=10.3390%2fmedicina57050404&partnerID=40&md5=12a73d73e5bb9e4d7d728a17b0b9d058https://scholars.lib.ntu.edu.tw/handle/123456789/586551The efficacy of combined intravitreal bevacizumab injection with systemic chemotherapy, palliative radiotherapy, and hormonal therapy to treat choroidal and orbital metastases is not known. Herein, we report the case of a 48-year-old woman with systemic chemotherapy-resistant choroidal and orbital metastases of the left eye originating from a stage IV invasive ductal carcinoma of the left breast. We describe the addition of a single intravitreal injection of bevacizumab in addition to treatment with systemic chemotherapy, hormonal therapy, and palliative radiotherapy. The patient’s outcome at 6-month follow-up was favorable, as the metastatic lesion reduced in size and visual acuity improved. Combined treatment with intravitreal bevacizumab injection, systemic chemotherapy, palliative radiotherapy, and hormonal therapy can resolve ocular metastatic lesions originating from breast cancers. ? 2021 by the authors. Licensee MDPI, Basel, Switzerland.Bevacizumab; Breast cancer; Choroidal metastasis; Intravitreal injection; Orbital metastasis[SDGs]SDG3angiogenesis inhibitor; bevacizumab; case report; female; human; intravitreal drug administration; middle aged; optical coherence tomography; Paget nipple disease; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Ductal; Female; Humans; Intravitreal Injections; Middle Aged; Tomography, Optical Coherencejournal article10.3390/medicina57050404339221372-s2.0-85105235757